99 related articles for article (PubMed ID: 28954807)
21. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
22. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
23. Expression of LMO2 in Prostate Carcinoma and Adjacent Prostatic Parenchyma.
Krušlin B; Vučić M; Mašić S; Kruljac I; Lež C; Ružić B; Spajić B; Ulamec M
Acta Clin Croat; 2018 Oct; 57(Suppl 1):56-60. PubMed ID: 30457249
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of four-and-a-half LIM domain protein-2 increases survival, migratory capacity, and paracrine function of human early outgrowth cells through activation of the sphingosine kinase-1 pathway: implications for endothelial regeneration.
Ebrahimian T; Arfa O; Simeone S; Lemarié CA; Lehoux S; Wassmann S
Circ Res; 2014 Jan; 114(1):114-23. PubMed ID: 24084691
[TBL] [Abstract][Full Text] [Related]
25. The expression of LMO2 protein in acute B-cell and myeloid leukemia.
Cobanoglu U; Sonmez M; Ozbas HM; Erkut N; Can G
Hematology; 2010 Jun; 15(3):132-4. PubMed ID: 20557670
[TBL] [Abstract][Full Text] [Related]
26. Direct and differential effects of stem cell factor on the neovascularization activity of endothelial progenitor cells.
Kim KL; Meng Y; Kim JY; Baek EJ; Suh W
Cardiovasc Res; 2011 Oct; 92(1):132-40. PubMed ID: 21636540
[TBL] [Abstract][Full Text] [Related]
27. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
29. Identification of DeltaEF1 as a novel target that is negatively regulated by LMO2 in T-cell leukemia.
Sun W; Yang S; Shen W; Li H; Gao Y; Zhu TH
Eur J Haematol; 2010 Dec; 85(6):508-19. PubMed ID: 20731704
[TBL] [Abstract][Full Text] [Related]
30. LMO2 blocks the UBA6-USE1 interaction and downstream FAT10ylation by targeting the ubiquitin fold domain of UBA6.
Wu C; Liu Y; Gu X; Zhu T; Yang S; Sun W
Biochem Biophys Res Commun; 2016 Sep; 478(3):1442-8. PubMed ID: 27569286
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.
Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A
Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362
[TBL] [Abstract][Full Text] [Related]
32. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
33. Targeting NCK-Mediated Endothelial Cell Front-Rear Polarity Inhibits Neovascularization.
Dubrac A; Genet G; Ola R; Zhang F; Pibouin-Fragner L; Han J; Zhang J; Thomas JL; Chedotal A; Schwartz MA; Eichmann A
Circulation; 2016 Jan; 133(4):409-21. PubMed ID: 26659946
[TBL] [Abstract][Full Text] [Related]
34. The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors.
de Boer J; Yeung J; Ellu J; Ramanujachar R; Bornhauser B; Solarska O; Hubank M; Williams O; Brady HJ
Leukemia; 2011 Feb; 25(2):321-30. PubMed ID: 21072044
[TBL] [Abstract][Full Text] [Related]
35. Elucidation of the role of LMO2 in human erythroid cells.
Inoue A; Fujiwara T; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Harigae H
Exp Hematol; 2013 Dec; 41(12):1062-76.e1. PubMed ID: 24041784
[TBL] [Abstract][Full Text] [Related]
36. A novel transcript of the LMO2 gene, LMO2-c, is regulated by GATA-1 and PU.1 and encodes an antagonist of LMO2.
Wang Q; Zhang M; Wang X; Yuan W; Chen D; Royer-Pokora B; Zhu T
Leukemia; 2007 May; 21(5):1015-25. PubMed ID: 17361224
[TBL] [Abstract][Full Text] [Related]
37. Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; Beverloo HB; Buijs-Gladdines J; van Wering ER; Horstmann M; Pieters R; Meijerink JP
Leukemia; 2008 Jul; 22(7):1434-7. PubMed ID: 18079736
[No Abstract] [Full Text] [Related]
38. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms.
Wiekmeijer AS; Pike-Overzet K; Brugman MH; van Eggermond MCJA; Cordes M; de Haas EFE; Li Y; Oole E; van IJcken WFJ; Egeler RM; Meijerink JP; Staal FJT
Exp Hematol; 2016 Sep; 44(9):838-849.e9. PubMed ID: 27302866
[TBL] [Abstract][Full Text] [Related]
40. High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.
Wu L; Xu Y; Wang Q; Ruan C; Drexler HG; Wu D; MacLeod RA; Chen S
Haematologica; 2015 Jun; 100(6):e233-6. PubMed ID: 25682596
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
